Tumor necrosis Factor (TNF) Bioactivity at the site of an acute cell-Mediated immune response is Preserved in rheumatoid arthritis Patients responding to anti-TNF Therapy by Byng-Maddick, R et al.
August 2017 | Volume 8 | Article 9321
Original research
published: 04 August 2017
doi: 10.3389/fimmu.2017.00932
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Pierre Miossec, 
Claude Bernard University Lyon 1, 
France
Reviewed by: 
Hubert Marotte, 
SAINBIOSE, France  
Paul Hasler, 
Kantonsspital Aarau, Switzerland
*Correspondence:
Mahdad Noursadeghi 
m.noursadeghi@ucl.ac.uk
†These authors have contributed 
equally to this work.
Specialty section: 
This article was submitted 
to Inflammation, 
a section of the journal 
Frontiers in Immunology
Received: 01 April 2017
Accepted: 21 July 2017
Published: 04 August 2017
Citation: 
Byng-Maddick R, Turner CT, 
Pollara G, Ellis M, Guppy NJ, 
Bell LCK, Ehrenstein MR and 
Noursadeghi M (2017) Tumor 
Necrosis Factor (TNF) Bioactivity at 
the Site of an Acute Cell-Mediated 
Immune Response Is Preserved in 
Rheumatoid Arthritis Patients 
Responding to Anti-TNF Therapy. 
Front. Immunol. 8:932. 
doi: 10.3389/fimmu.2017.00932
Tumor necrosis Factor (TnF) 
Bioactivity at the site of an acute 
cell-Mediated immune response is 
Preserved in rheumatoid arthritis 
Patients responding to anti-TnF 
Therapy
Rachel Byng-Maddick1,2†, Carolin T. Turner 1†, Gabriele Pollara1, Matthew Ellis 3,  
Naomi J. Guppy4, Lucy C. K. Bell 1, Michael R. Ehrenstein2,5† and Mahdad Noursadeghi1,5*†
1 Division of Infection and Immunity, University College London, London, United Kingdom, 2 Division of Medicine, University 
College London, London, United Kingdom, 3 Division of Neuropathology, Institute of Neurology, University College London, 
London, United Kingdom, 4 UCL Advanced Diagnostics, London, United Kingdom, 5 National Institute for Health Research, 
University College London Hospitals, Biomedical Research Centre, London, United Kingdom
The impact of anti-tumor necrosis factor (TNF) therapies on inducible TNF-dependent 
activity in humans has never been evaluated in vivo. We aimed to test the hypothesis 
that patients responding to anti-TNF treatments exhibit attenuated TNF-dependent 
immune responses at the site of an immune challenge. We developed and validated four 
context-specific TNF-inducible transcriptional signatures to quantify TNF bioactivity in 
transcriptomic data. In anti-TNF treated rheumatoid arthritis (RA) patients, we measured 
the expression of these biosignatures in blood, and in skin biopsies from the site of 
tuberculin skin tests (TSTs) as a human experimental model of multivariate cell-mediated 
immune responses. In blood, anti-TNF therapies attenuated TNF bioactivity following 
ex vivo stimulation. However, at the site of the TST, TNF-inducible gene expression and 
genome-wide transcriptional changes associated with cell-mediated immune responses 
were comparable to that of RA patients receiving methotrexate only. These data demon-
strate that anti-TNF agents in RA patients do not inhibit inducible TNF activity at the site 
of an acute inflammatory challenge in  vivo, as modeled by the TST. We hypothesize 
instead that their therapeutic effects are limited to regulating TNF activity in chronic 
inflammation or by alternative non-canonical pathways.
Keywords: tumor necrosis factor, anti-tumor necrosis factor, rheumatoid arthritis, tuberculin skin test, 
transcriptional profiling
inTrODUcTiOn
Tumor necrosis factor (TNF) is a pleiotropic cytokine that is transcriptionally activated in response 
to a variety of stimuli during inflammation, infection, and stress. Its non-redundant role in the 
immune system is apparent in TNF-deficient mice, which have no phenotypic abnormalities in the 
steady state, but are unable to mount organized immune responses and thus suffer from an increased 
TaBle 1 | Inclusion and exclusion criteria for study participants.
inclusion criteria exclusion criteria
Age 18–75
Male or female
Confirmed diagnosis of rheumatoid 
arthritis (RA), treated with either 
adalimumab, infliximab, etanercept or 
methotrexate, with low disease activity
Previous exposure to TB (previous 
active disease, previous positive 
tuberculin skin test, known contact 
with TB or from high demographic 
risk area)
Age <18 or >75
Other diseases of the immune system
Other treatments affecting the immune 
system
Very high disease activity of RA 
(DAS28 > 5.1)
Previous history of reaction to 
lignocaine, purified protein derivative, or 
keloid scarring
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susceptibility to infection (1–4). Upon cellular activation, TNF is 
mostly produced by mononuclear phagocytes but is also expressed 
by neutrophils, lymphocytes, endothelial cells, and fibroblasts 
(5, 6). The membrane-bound precursor and the cleaved, soluble 
form of TNF are both biologically active and exert their effects via 
two structurally distinct transmembrane glycoprotein receptors. 
TNF receptor (TNFR) 1 is expressed on almost all nucleated cells 
and TNFR2 (p75) expression is restricted to cells of the immune 
system (7). Engagement of these receptors initiates intracellular 
signaling pathways leading to transcription of TNF-responsive 
genes, which in turn regulate cell proliferation and apoptosis or 
induce pro-inflammatory mediators (5, 8, 9).
Excessive TNF activity contributes to the complex patho-
genesis of rheumatoid arthritis (RA) (10), associated with a 
pro-inflammatory cascade that includes the production of IL-1 
and IL-6, and drives tissue destruction (11). The use of anti-TNF 
therapies in RA has substantially improved the outcome and 
clinical course of the disease (12). The five licensed TNF inhibi-
tors comprise the anti-TNF antibodies infliximab, adalimumab, 
and golimumab, the TNFR2 Fc fusion protein etanercept (ETN), 
and the pegylated Fab fragment certolizumab. All of these were 
developed to competitively inhibit the binding of TNF to its cog-
nate cellular receptors and consequently block its biological activ-
ity. However, a comprehensive characterization of their in vivo 
inhibitory effect on TNF activity has yet to emerge. Variable 
effects on the level of TNF itself in serum or synovium of RA 
patients have been described, which do not necessarily correlate 
with the clinical response to anti-TNF therapy (13–16). In gen-
eral, the level of pro-inflammatory mediators in serum and syn-
ovium, and pro-inflammatory cytokine production by peripheral 
blood mononuclear cells (PBMC) is reduced following anti-TNF 
therapy (17–19). While these data suggest that anti-TNF therapies 
ameliorate the immunopathogenesis of RA, they do not reveal the 
contexts in which anti-TNF therapies regulate TNF activity. We 
do not know if they block inducible TNF activity in both acute 
and chronically inflamed tissues or if they mediate their effects 
by blocking TNF in the circulation or hematopoetic compart-
ments, where TNF may have important roles in shaping systemic 
immune responses. These gaps in our knowledge limit further 
refinement of biological therapies for inflammatory diseases. 
Moreover, we have described at least one indirect mechanism of 
action, in which anti-TNF antibodies unexpectedly promoted an 
interaction between membrane-bound TNF on monocytes and 
TNFR2 on regulatory T cells leading to enhanced Treg activity 
that may contribute to disease control (20, 21). ETN also binds 
and neutralizes lymphotoxin α (LTA) (22), suggesting another 
putative mechanism for non-canonical effects of anti-TNF agents.
A well-recognized complication of anti-TNF therapy is 
increased susceptibility to granulomatous infections, especially 
with Mycobacterium tuberculosis (Mtb) (23, 24), in which cell-
mediated immune responses are thought to represent the princi-
pal mechanism of host defense (25). The role of TNF in immune 
protection against tuberculosis was primarily derived from 
observations in TNFR deficient mice, which do not assemble 
well-formed granuloma (26, 27). This observation was replicated 
by administration of anti-TNF agents in wild type mice (28, 29). 
Consequently, increased risk of tuberculosis associated with 
anti-TNF therapy is also widely interpreted to be due to deficient 
TNF activity in cell-mediated immune protection, but direct 
evidence for this is lacking. Interestingly, anti-TNF antibodies 
such as infliximab and adalimumab invoke significantly greater 
risk of active tuberculosis in man, than the soluble TNFR, ETN 
(30–32). Possible mechanisms for the differential risk is reported 
to be apoptosis of monocytes and activated T cells (33–35), or 
depletion of Mtb reactive CD8 T  cells by antibody binding to 
membrane TNF (36).
We have previously described transcriptional profiling at the 
site of the tuberculin skin test (TST) to make molecular and 
systems level assessments of in vivo human immune responses 
at the site of a standardized experimental challenge (37, 38). 
Clinical inflammation in the TST has been widely used as a 
surrogate for T cell memory for mycobacterial antigens (39), but 
transcriptional profiling of biopsies from the injection site reflects 
all the components of integrated innate and adaptive immune 
responses, each of which can be quantified with independently 
derived transcriptional modules (38, 40). Importantly, this 
approach also revealed immune responses in the absence of clini-
cally evident inflammatory induration, allowing unprecedented 
sensitivity to measure immune responses that were previously 
described as anergic (37, 38). In the present study, we aimed to 
test the hypothesis that anti-TNF treated RA patients will exhibit 
attenuated TNF-dependent transcriptional responses at the site 
of the TST, and consequently evaluate the role of TNF in genome-
wide assessments of cell-mediated immune responses.
MaTerials anD MeThODs
study approval
This study was approved by UK National Research Ethics Service 
(reference no: 11/LO/1863).
study Population and sampling
Healthy volunteers and adult patients with RA, treated with meth-
otrexate (MTX), adalimumab, infliximab, or ETN, were invited 
to participate subject to selected criteria (Table  1). Written 
informed consent was obtained from all participants. Disease 
activity in RA patients was assessed using the Disease Activity 
Score of 28 commonly involved joints in RA (DAS28), comprising 
TaBle 2 | Summary data for study participants undergoing skin tests.
Participant characteristics Tuberculin skin test recipients saline recipients
hV MTX Mab eTn hV MTX Mab eTn
Number 10 10 10 8 3 3 3 3
Age (median/range) 32.5 (28–42) 61 (53–69) 59.5 (38–75) 62.5 (30–67) 31 (29–38) 76 (57–76) 68 (66–74)% 36 (31–61)
Gender (% female) 60 80 60 62.5 10 100 66.7 100
Ethnicity White British (%) 70 100 70 87.5 100 66.7 100 100
White other (%) 20 0 10 0 0 0 0 0
Asian Indian (%) 10 0 0 0 0 33.3 0 0
Other (%) 0 0 20 12.5 0 0 0 0
RF status Positive (%) n/a 60 40 37.5 n/a 66.7 66.7 33.3
Negative (%) n/a 40 40 25 n/a 33.3 33.3 33.3
Unknown (%) n/a 0 20 37.5 n/a 0 0 33.3
CRP mg/dL (median/range) n/a 2.3 (<0.6–11.0) 1.0 (<0.6–2.4) 3.2 (<0.6–11) n/a 2.4 (2.1–2.5) 2.15 (<0.6–3.1) 0.9 (<0.6–0.9)
DAS28 (median/range) n/a 2.0 (0.6–2.8) 2.6 (0.8–3.5) 2.3 (1.5–4.3) n/a 3.0 (2.9–3.0) 3.6 (1.9–4.2) 2.4 (2.3–2.6)
Anti-CCP antibodies (%) n/a 40 50 25 n/a 33 33 33
IFNγ ELISpots/2 × 105 PBMC 
(median/range)
52.3 (11–00) 48.3 (10–25) 130.4 (15–300) 35.5 (10.5–38) 41 (15–98) 13.5 (13–50) 43.5 (38–60) 100 (20–122)
HV, healthy volunteer; MTX, methotrexate only group; Mab, monoclonal antibody group; ETN, etanercept group; CRP, C-reactive protein; DAS28, disease activity score of 28 joints; 
CCP, cyclic citrullinated peptide; PBMC, peripheral blood mononuclear cells.
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the number of swollen and tender joints, the erythrocyte sedi-
mentation rate, and a visual analog scale of the patient’s subjective 
perception of pain marked out of 100 (41, 42).
Participants with positive peripheral blood IFNγ release assays 
as evidence of antimycobacterial T  cell memory (see below) 
received either intradermal TST or saline injections in the volar 
aspect of the forearm as previously described (37, 38). At 72 h, the 
maximum diameter of inflammatory induration was measured, 
and two 3 mm adjacent punch biopsies were obtained over the 
center of the injection sites. In addition, whole blood was taken 
from further participants in each study group for ex vivo stimula-
tion with 10 ng/mL recombinant human TNF (Life Technologies). 
Demographic, clinical, and laboratory data for each study group 
are summarized in Table 2 and for each participant in Data Sheet 
S3 in Supplementary Material, including all available data on pre-
vious blood IFNγ release assays or TB treatment. No participants 
had any evidence of active TB or received any treatment for TB 
during their participation in the study.
Peripheral Blood iFnγ release assays
Participants were screened for antimycobacterial T cell memory 
by peripheral blood IFNγ release assays using QuantiFERON-TB 
Gold tests (Qiagen) according to the manufacturer’s instructions 
or IFNγ ELISpot responses to purified protein derivative (PPD, 
Statens Serum Institute). Briefly, PBMC were obtained by density 
gradient centrifugation of heparinized whole blood with Ficoll-
Paque PLUS (GE Healthcare Biosciences). Sterile, clear 96-well 
filter plate with a PVDF base membrane (Merck Millipore) were 
coated with 1  µg/mL antihuman IFNγ antibody (eBioscience) 
for 24 h at 4°C, prior to the addition of 2 × 105 PBMC per well 
and PPD 10 µg/mL (SSI, Denmark), soluble anti-CD3 (HIT 3a) 
(eBioscience) as a positive control, or vehicle control. Plates 
were incubated for 48 h at 37°C. IFNγ production was detected 
using 1 µg/mL of biotinylated detection antibody (eBioscience), 
1  µg/mL of streptavidin alkaline phosphatase (ALP) conjugate 
(Calbiochem) and BCIP/NBT substrate for ALP (Merck). The 
reaction was allowed to develop in the dark and stopped by 
addition of distilled water. Reactive foci were counted using AID 
ELISpot Software version 5.0 on the AID ELISpot Reader.
Whole genome Transcriptional Profiling 
and analysis
Total RNA from peripheral blood, monocyte-derived macrophages 
(MDM), and skin biopsy samples was purified for genome-wide 
transcriptional profiling as previously described (37, 38). All 
novel gene expression data are available on ArrayExpress1 under 
accession numbers E-MTAB-5095 [lipopolysaccharide (LPS)/
ETN-MDM module], E-MTAB-5094 (whole blood stimulation), 
and E-MTAB-5093 (skin biopsies). Differential gene expression 
was assessed in MultiExperiment Viewer v4.9.0.2 Two-tailed 
t-tests were used to derive TNF modules from ex vivo and cell 
culture experiments. Mann–Whitney tests were used to compare 
TST and saline injection sites. A p value of <0.05 was considered 
significant. This statistical threshold to identify significant dif-
ferentially expressed genes was complemented by using a twofold 
change filter and statistical enrichment in upstream regulator 
analysis, performed using Ingenuity Pathway Analysis (Qiagen); 
and pathway analysis using InnateDB,3 visualized as network 
diagram in Gephi v0.8.2 beta.4 Principal component analysis was 
performed using the prcomp function in R.5
1 https://www.ebi.ac.uk/arrayexpress/.
2 http://mev.tm4.org/.
3 http://www.innatedb.com.
4 https://gephi.org/.
5 www.r-project.org.
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Derivation of Transcriptional Modules
Derivation and validation of the TNF-MDM module was previ-
ously described (38). To generate the LPS/ETN-MDM module, 
human blood MDM cultures (43) were primed for 1 h ± 10 μg/mL 
ETN (Pfizer) before ultra-pure LPS (100  ng/mL; Invivogen) 
stimulation for 24 h (n = 3 per group). Transcriptional profiling 
of stimulated MDM was then performed as previously reported 
(38). LPS-inducible genes (>2-fold) were defined by comparison 
with transcriptional data from unstimulated MDM (n =  17). 
Among these LPS response genes, those that were attenuated 
significantly (>2-fold) in the presence of ETN were used as the 
LPS/ETN-MDM module. To derive a TNF-specific module in 
keratinocytes (TNF-KC module), we made use of previously 
published transcriptomic data from primary human keratino-
cytes (KCs) stimulated with a selection of cytokines, including 
TNF (44). Significant transcriptional responses (>4-fold) to 24 h 
TNF stimulation (10 ng/mL) were identified by comparison to 
unstimulated KCs, excluding genes that were also upregulated 
(>2-fold) by IFNγ, IL17 or IL22. The TNF-blood module was 
obtained by comparison of transcriptomes from whole blood 
(n = 4 healthy volunteers) incubated at 37°C for 3 h ±10 ng/mL 
recombinant human TNF, to identify transcripts that were sig-
nificantly upregulated by >2-fold. The gene lists that make up 
each TNF module are listed in Data Sheet S1 in Supplementary 
Material. A human T  cell-specific transcriptional signature 
(module M19) (45) and gene lists representing IFNγ activity 
and responses to Mtb (38, 40) have been published previously. 
Module scores represent the geometric mean log2 expression of 
all contributing genes and module enrichment represents the 
difference in module scores between data from TST and saline 
injection sites.
histology and immunohistochemistry  
of skin Biopsy specimens
Punch skin biopsies for histological analysis were snap frozen 
in OCT Compound (Tissue-Tek). Frozen sections were care-
fully thawed and fixed in 4% neutral buffered formalin, then 
embedded in paraffin wax (Sakura). 3  µM sections were cut 
and stained using the Leica Bond III automated immunostain-
ing platform, with the Leica Bond Polymer Refine detection 
kit (Leica DS9800) and a DAB chromogen. More specifically, 
antihuman antibodies against CD3 (clone LN10) (Leica NCL-
L-CD3-565) and matrix metalloproteinase (MMP) 9 (clone 
56-2A4) (Millipore MAB3309) were used. Whole slide images 
of the histology sections were acquired with an Axio-Scan 
microscope using Zen 2 core software at ×20 magnification 
and are presented without any subsequent processing. Digital 
image analysis was performed using Definiens AG (Munich) 
Tissue Studio 4.3 software. Tissue detection automatically iden-
tified all the tissue within each image, then a machine learning 
method was used to separate the sample from background and 
non-tissue regions, and segment the sample into dermis and 
epidermis; manual correction was used to ensure valid separa-
tion of these regions of interest (ROI). A fixed threshold was 
then applied to each ROI to identify the chromogen positive 
areas (μm2), which is represented as a percentage of the total 
tissue/ROI area.
resUlTs
Derivation of TnF-inducible 
Transcriptional Modules
Current anti-TNF therapies aim to block the bioactivity of TNF 
rather than expression or secretion of TNF. Therefore, measure-
ment of TNF function rather than TNF levels is required to assess 
the effects of anti-TNF therapies. TNF exerts its biological func-
tions via stimulation of the TNFRs and intracellular signaling 
cascades that converge on regulation of transcription factors and 
consequently gene expression (46). Our first aim was to derive 
and validate gene expression modules, which could be used to 
detect and quantify functional TNF activity. In MDM, we had 
previously reported one such module that discriminated cellular 
responses to stimulation with recombinant TNF (TNF-MDM 
module) from a selection of other cytokines including IFNγ, IL4, 
and IL13 (38). In the present study we reasoned that the tran-
scriptional response to TNF stimulation may be influenced by its 
cellular context or the presence of other inflammatory mediators. 
Any individual gene expression module may be inadequate to 
detect all TNF activity. Therefore, we derived three novel TNF-
inducible gene expression modules by alternative approaches.
We first sought to identify gene expression attributable to 
TNF in the presence of other bioactive cytokines. We used innate 
immune stimulation of MDM with bacterial LPS as a prototypic 
stimulus to invoke secretion of a wide range of immunologically 
active factors, including TNF, contributing to LPS-inducible 
gene expression by their downstream autocrine and paracrine 
activity. To identify gene expression attributable to LPS-induced 
TNF, we compared the transcriptome of MDM 24  h after LPS 
stimulation in the presence and absence of ETN. Since ETN 
blocks the activity of LTA as well as that of TNF, we analyzed 
previously published data obtained from LPS stimulation in the 
same MDM model for induction of TNF and LTA expression 
(47, 48). As expected LPS induced robust upregulation of TNF 
expression in the primary transcriptional response (Figure 1A). 
This response would be expected to drive TNF-dependent gene 
expression changes at subsequent time points. In contrast, there 
was no induction of LTA. Therefore, gene expression attenuated 
by ETN in LPS-stimulated MDM unequivocally reflected endog-
enous TNF activity. We found significantly lower expression of 77 
genes in the presence of ETN (Figure 1B), which we infer to be 
TNF responsive. We refer to these genes as the LPS/ETN-MDM 
module. In addition, we tested the effect of anti-TNF therapies on 
functional TNF activity in blood and derived a TNF gene expres-
sion module by identifying significantly upregulated genes fol-
lowing ex vivo whole blood stimulation with TNF (Figure 1C). 
We refer to this as the TNF-blood module. Our ultimate aim was 
to evaluate TNF activity in response to an in vivo immunologi-
cal challenge using the TST (37, 38). Differential transcriptional 
responses to the same stimulus in different cell types are widely 
recognized (49). Therefore, we took advantage of previously pub-
lished transcriptomic data from KCs stimulated with a selection 
of cytokines including TNF (44) to derive a TNF-specific module 
in keratinocytes (TNF-KC module) (Figure 1D).
Direct comparison of the genes included in each of the four 
modules (Data Sheet S1 in Supplementary Material) associated 
FigUre 1 | Derivation of transcriptional modules to measure tumor necrosis factor (TNF) activity. (a) Relative expression of TNF and lymphotoxin α (LTA) in 
monocyte-derived macrophage (MDM) cultures before and after 3 h stimulation with lipopolysaccharide (LPS) 100 ng/mL derived from previously published 
microarray data (ArrayExpress accession No: E-MEXP-1904 and E-MEXP-2032). Bars represent mean + SD (n = 3–5) and *p < 0.05, t-test. (B) Volcano plot of the 
effect of etanercept (ETN) on LPS-induced genes in MDM after 24 h. Open circles (green) represent 77 genes that were significantly (p < 0.05, t-test) attenuated 
(>2-fold) in the presence of ETN to give the “LPS/ETN-MDM” module. (c) Transcriptional response to TNF (10 ng/mL for 24 h) in ex vivo whole blood stimulation 
experiments. Open circles (red) represent 104 genes that were significantly (p < 0.01, t-test) upregulated (>2-fold) in response to TNF to give the “TNF-blood” 
module. (D) 4-way Venn diagram showing the overlap of keratinocyte (KC) genes significantly (p < 0.05, t-test) upregulated (>2-fold by IFNγ, IL22, IL17, or 4-fold by 
TNF) after 24 h stimulation. The 10 TNF-specific genes were used to give the “TNF-KC” module. (e) Venn diagram of the genes making up each TNF transcriptional 
modules, derived as described in panels (B–D) and by Bell et al. (“TNF-MDM”).
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with TNF activity showed only modest overlap (Figure  1E). 
Cross-validation of each gene list in the different experiments 
which were used to derive them also highlighted their context 
specificity. Modules derived in MDM were not enriched in TNF-
stimulated KCs and modules derived in KCs were not enriched 
in TNF- or LPS-stimulated MDM (Figure  2). Importantly, 
however, independent bioinformatic analysis of predicted 
upstream regulators of each of these gene lists showed statistically 
robust associations with TNF (Data Sheet S2 in Supplementary 
Material).
anti-TnF Therapy attenuates TnF-
inducible gene expression in Blood
Previous reports have interpreted the reduction in circulating 
pro-inflammatory mediators following initiation of anti-TNF 
therapies in RA as evidence for inhibition of TNF activity 
(17–19). Therefore, we reasoned that anti-TNF therapy would be 
associated with steady state reduction of TNF-dependent gene 
expression in blood and would attenuate upregulation of these 
gene expression modules following ex vivo stimulation with TNF. 
We quantified expression of the blood-TNF module before and 
after ex vivo TNF stimulation of blood from RA patients treated 
with anti-TNF therapies and compared these to blood samples 
from RA patients on MTX only. To avoid the confounding of 
differential disease activity, we restricted recruitment to patients 
on a stable treatment regimen for at least three months and who 
showed low levels of background inflammation, using C-reactive 
protein and the RA disease activity score of 28 joints (DAS28) 
(Table 2; Data Sheet S3 in Supplementary Material). There were 
no significant differences in DAS28 scores between RA patients 
in the different treatment groups (Figure 3A), as a biomarker of 
disease activity (42). All had a reduction of DAS28 score of >1.2 
from pretreatment levels, thereby allowing them to continue on 
their current treatment regimen. None had a residual DAS28 
score >5.1, which would represent ongoing highly active disease. 
In addition, the proportions of anti-cyclic citrullinated peptide 
antibody as a prognostic biomarker of disease (50) were not 
significantly different between the groups (Table 2).
Baseline levels of TNF-dependent gene expression were not 
significantly different in blood from RA patients on anti-TNF 
therapies compared to that of patients on MTX (Figure  3B). 
Ex vivo whole blood stimulation with TNF upregulated the 
FigUre 3 | Anti-tumor necrosis factor (TNF) therapy attenuates TNF-
inducible gene expression in blood. (a) Distribution of DAS28 scores in 
rheumatoid arthritis (RA) patients treated with methotrexate (MTX) only, 
anti-TNF antibodies (Mab), or etanercept (ETN). Dotted lines represent 
threshold values for disease in remission (<2.6), mild disease activity (<3.2), 
and moderate disease activity (<5.1). Transcriptional TNF activity, represented 
by the blood-derived TNF gene expression module score, (B) in peripheral 
blood of RA patients treated with MTX (n = 4), monoclonal anti-TNF 
antibodies (n = 4), or ETN (n = 4) at baseline, and (c) the change (Δ) in 
module score associated with TNF stimulation (10 ng/mL for 3 h). Data 
points were derived from individual experiments. Line represents the median. 
*p < 0.05, Mann–Whitney test.
FigUre 2 | Cross-validation of transcriptional tumor necrosis factor (TNF) 
modules in the different experiments they were derived from. Module scores, 
calculated as geometric mean expression of the genes contributing to each 
module, in genome-wide transcriptomic data from monocyte-derived 
macrophages (MDM), keratinocytes (KC), and blood stimulated with ±TNF or 
lipopolysaccharide (LPS)-stimulated MDM ± etanercept (ETN). Bars represent 
mean + SD (n = 3–5). *p < 0.05, t-test.
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expression of each of the TNF-dependent modules in all groups of 
patients, but this increase was significantly attenuated in patients 
on anti-TNF therapies (Figure 3C). In addition, we found that 
TNF was among the top predicted upstream regulators of all genes 
significantly attenuated by anti-TNF therapy in TNF-stimulated 
blood (Data Sheet S2 in Supplementary Material). Therefore, we 
concluded that in keeping with their expected effect, anti-TNF 
therapies attenuated the functional response to circulating TNF, 
which we modeled by ex vivo stimulation of peripheral blood.
Quantitation of TnF activity in the TsT
Next, we tested the effect of anti-TNF therapies on TNF activity at 
the site of an immune challenge in vivo. To do so, we undertook 
transcriptional profiling of skin biopsies from the site of TSTs 
in individuals with antimycobacterial T  cell memory (Table  2; 
Data Sheet S3 in Supplementary Material). In healthy volunteers, 
the TST invokes a multivariate immune response that com-
prises innate immune responses, immune cell recruitment, and 
cytokine responses (Figure 4; Data Sheet S4 in Supplementary 
Material) (37, 38). This includes robust enrichment of TNF gene 
expression itself and of all four TNF-dependent gene expression 
modules derived from MDM, KCs, and blood cells, representing 
a broad range of TNF-responsive cells in the context of the TST 
(Figures 5A,B).
To extend the assessment of TNF activity beyond transcrip-
tional responses to the protein level, we also immunostained TST 
biopsy sites to quantify expression of the MMP9 (Figure  5C). 
MMP9 has been associated with TNF activity in previous studies 
(51). It is also a component of the TNF-KC module and therefore 
a specific protein target in the skin to discriminate between TNF 
and IFNγ activity (Figure 1D; Data Sheet S1 in Supplementary 
Material). Six of the ten healthy volunteers undergoing TST injec-
tion showed increased MMP9 protein expression compared to 
participants receiving control saline injections (Figure 5D). The 
variability in TNF modules and MMP9 immunostaining each 
demonstrated a statistically significant correlation with TNF 
transcript levels among different individuals (Figures  5E,F). 
These correlations consolidated the evidence for a functional 
relationship between TNF expression and the independently 
derived TNF-inducible transcriptional modules or MMP9 
immunostaining. Hence, we conclude that the TST invokes a 
functional TNF response, within which we can quantify variation 
in TNF bioactivity.
Functional TnF activity is Preserved  
at the site of an immunological challenge 
In Vivo Despite anti-TnF Therapy
Rheumatoid arthritis patients treated with anti-TNF therapies 
or MTX only, had comparable peripheral blood IFNγ ELISpot 
FigUre 4 | The transcriptional tuberculin skin test (TST) response of healthy volunteers. (a) Network graph of the top 10 Reactome pathways enriched among the 
genes upregulated in TST (n = 10) compared to saline (n = 3) samples from healthy volunteers. Red nodes represent pathways, and blue nodes represent genes. 
Node and label font size denote the significance of the respective pathway and are proportional to its −log10 p value. (B) Transcriptional module scores representing 
T cell recruitment, IFNγ activity, and responses to Mycobacterium tuberculosis (Mtb) in each biopsy. (c) Representative immunostaining of CD3 in skin biopsy 
samples from the site of TST and saline injections (scale bar = 500 µM). (D) Quantitation of CD3 immunostaining in each biopsy. Data points represent individual 
participants, and group medians are indicated by red lines. *p < 0.05, **p < 0.01 in Mann–Whitney tests.
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responses to tuberculin/PPD stimulation (Figure 6A), indicating 
that these study groups had equivalent T cell memory responses 
for tuberculin irrespective of any differences in their past history 
of TB exposure or treatment. In these participants, we defined 
an integrated TST transcriptional signature. This signature 
comprised 595 genes that were significantly enriched in the TST 
compared to saline injection sites in at least one study group 
(Figure 6B). Bioinformatic analysis of these genes reflected the 
same immune pathways evident in the TST transcriptome of 
healthy individuals (Figure 6C).
Principal component analysis of the integrated TST signature 
genes, as well as enrichment of T  cell-associated and IFNγ-
dependent gene expression modules, indicated that the major 
features of transcriptional responses in the TST of RA patients 
were not affected by anti-TNF therapy (Figure 7).
The TST response in RA patients included enrichment of 
TNF gene expression, which was similar in all patient groups 
and therefore not affected by anti-TNF therapy (Figure  8A). 
Surprisingly, however, comparable levels of the TNF-dependent 
gene expression modules were also observed in all the study 
groups (Figure  8B). Likewise, MMP9 immunostaining repre-
senting a protein biomarker of TNF activity was comparable in 
anti-TNF treated and control patients (Figures 8C,D). Therefore, 
we conclude that anti-TNF therapy in RA patients does not 
inhibit inducible TNF function during a prototypic cell-mediated 
immune response at the site of immune challenge.
FigUre 5 | Quantitation of tumor necrosis factor (TNF) activity in the tuberculin skin test (TST) among healthy volunteers. (a) Relative TNF gene expression,  
(B) module scores of four separate TNF modules derived from genome-wide microarrays, and (c) representative immunostaining of matrix metalloproteinase (MMP) 
9 in skin biopsy samples from the site of TST and saline injections (scale bar = 500 µM). (D) Positive immunostaining for matrix metalloproteinase (MMP) 9 in skin 
biopsies from the site of TST (n = 10) or control saline injections (n = 3) in healthy volunteers. Data points represent individual experiments. *p < 0.05, **p < 0.01, 
Mann–Whitney test. (e,F) Correlation between TNF expression and each of the TNF module scores or positive log2 MMP9 immunostaining. Correlation coefficients 
(r) and p values were derived from Pearson correlation analyses. **p < 0.01, ***p < 0.001, ****p < 0.0001.
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DiscUssiOn
The rationale for the development of anti-TNF therapies in RA 
was based on local expression of TNF at the site of disease, our 
understanding of its functional role in pro-inflammatory immune 
cell recruitment to tissues and data from animal models in which 
over expression of human TNF caused a chronic inflammatory 
arthritis that could be ameliorated by anti-TNF therapy (52). 
In this context, the unequivocal therapeutic effects of anti-TNF 
antibodies and ETN in RA led to two conclusions. First, anti-
TNF therapies mediate their beneficial effect by inhibiting TNF 
activity at the site of disease and consequently, TNF function 
makes an essential contribution to the immunopathogenesis of 
disease. Second, the same rationale applied to the detrimental 
effect of TNF inhibition, as increased risk of certain infections 
among patients on anti-TNF therapies (31, 53) suggested that 
TNF activity is an essential component of protective immune 
responses.
Several lines of evidence suggest that the effects of anti-TNF 
agents are not wholly understood. For example, it has become 
evident that anti-TNF antibodies and ETN have differential 
biological activity. Although they mediate similar therapeutic 
effects in RA, anti-TNF antibodies but not ETN are effective in 
other chronic inflammatory disease such as Crohn’s colitis (54). 
Likewise, the use of anti-TNF antibodies incurs significantly 
greater risk of active tuberculosis than that of ETN (30–32). 
In addition, we have previously shown that anti-TNF antibodies, 
but not ETN, induce increased emergence of functionally active 
regulatory T cells (20). Counterintuitively, this last example may 
be mediated by augmentation of TNF function through enhanc-
ing the interaction of membrane-bound TNF and TNFR2 (21). 
Therefore, the biological effects of anti-TNF therapies may extend 
FigUre 6 | The transcriptional tuberculin skin test (TST) response of rheumatoid arthritis (RA) patients. (a) Distribution of quantitative IFNγ ELISpot results in RA 
patients treated with methotrexate (MTX) only, anti-TNF antibodies (Mab), or etanercept (ETN). Each data point represents an individual patient. (B) Number and 
overlap of genes upregulated in TST compared to saline samples in patients treated with MTX, monoclonal anti-TNF antibodies (Mab), or the soluble tumor necrosis 
factor (TNF) receptor ETN. The total number of genes displayed in this Venn diagram was combined in the integrated TST module. (c) Network graph of the top 10 
Reactome pathways enriched in the integrated TST signature genes. Red nodes represent pathways, and blue nodes represent genes. Node and label font size 
denote the significance of the respective pathway and are proportional to its −log10 p value.
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beyond the canonical view that they block TNF activity at the site 
of immune responses in tissue. In fact, there are no experimental 
data that conclusively show this effect in man.
To test this question directly, we adopted a human experimental 
challenge approach using the TST as a standardized stimulus with 
which to invoke a focus of cell-mediated immune responses (37). 
Transcriptional profiling from skin punch biopsies from the site 
of the TST afforded us the opportunity to make comprehensive 
genome-wide assessments of immune responses at the molecular 
level with unprecedented sensitivity. We complemented this 
approach with the generation of independent experimentally 
derived TNF-dependent gene expression modules representing 
the functional bioactivity of TNF. Our evaluation of TNF activity 
at the transcriptional level revealed striking differences between 
TNF-dependent transcriptional responses in macrophages, 
blood cells, and KCs. The mechanisms underlying the context 
specificity in the functional activity of TNF likely reflect distinct 
epigenetic landscapes in different cell types (55). Despite the 
limited overlap between each of the four TNF-dependent gene 
expression modules we derived, in silico bioinformatics analysis 
yielded TNF as one of the top predicted upstream transactivator 
of each list of genes. These independently derived transcriptional 
modules associated with different cell types present at the site 
of the TST, namely, KCs, macrophages, and recruited blood 
leukocytes enhanced the sensitivity of our analysis and provided 
cross-validation.
In healthy subjects, we showed that TNF expression was 
enriched in the TST and that the variability in its enrichment 
FigUre 8 | Inducible tumor necrosis factor (TNF) activity is preserved in the TST of rheumatoid arthritis (RA) patients despite anti-TNF therapy. The change in  
(a) TNF gene expression and (B) each of the four TNF-dependent gene expression modules in TST skin biopsies from RA patients treated with methotrexate  
(MTX, n = 10), monoclonal anti-TNF antibodies (Mab, n = 10), or etanercept (ETN, n = 8), compared to control saline injections (n = 3 per group). (c) Representative 
images of MMP9 immunohistochemical staining (scale bar = 500 μm) and (D) positive MMP9 staining in skin biopsies from the same patients. Data points represent 
individual experiments. Line represents the median. TST, tuberculin skin test; MDM, monocyte-derived macrophage; LPS, lipopolysaccharide; KC, keratinocyte; 
MMP9, matrix metalloproteinase 9.
FigUre 7 | The transcriptional tuberculin skin test (TST) response in patients 
with rheumatoid arthritis. (a) Principal component (PC) analysis of integrated 
TST signature genes showed no treatment-specific clustering in PC1 and 
PC2, which together explained 83% of variation in this data set. Data points 
represent individual experiments. (B) Transcriptional modules representing 
enrichment of T cells, IFNγ activity, and innate immune responses to 
Mycobacterium tuberculosis (Mtb) in TST compared to saline baseline as 
shown by log2 module enrichment scores. Individual patients are represented 
with separate data points, and group medians are indicated by black lines. 
MTX, methotrexate; Mab, monoclonal anti-TNF antibodies; ETN, etanercept.
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correlated with concordant enrichment of each of the four TNF-
dependent transcriptional modules. In addition, we extended this 
analysis to the protein level, by showing correlation with MMP9 
as a TNF-inducible protein (56). Taken together, these data 
showed unequivocally that the TST invokes a functional TNF 
response and that we can quantify variability in TNF bioactivity 
in situ within this response.
To test the effects of anti-TNF agents, we sought to compare 
RA patients with quiescent disease on MTX to those receiving 
anti-TNF agents. In blood, baseline TNF bioactivity repre-
sented by the expression of TNF modules was not significantly 
different between RA patients on MTX and those on anti-TNF 
therapies. Therefore, our data suggest that the widely reported 
diminution of pro-inflammatory mediators in RA patients 
with quiescent disease following anti-TNF therapy may not 
be related to a targeted reduction in steady state expression 
of TNF-dependent gene expression but could simply represent 
successful control of active disease in patients on treatment 
with MTX or anti-TNF therapies, albeit through possibly 
divergent mechanisms. Nonetheless, we confirmed that enrich-
ment of TNF-dependent gene expression following ex vivo 
TNF stimulation of whole blood was significantly attenuated 
in blood from patients on anti-TNF agents. These findings are 
in keeping with previous reports of neutralization of TNF bio-
activity by plasma from patients receiving infliximab (57, 58). 
However, in the same groups of patients, receipt of anti-TNF 
agents did not attenuate the enrichment of the TNF-dependent 
transcriptional modules or MMP9 immunostaining within the 
TST. Hence, we concluded that although anti-TNF agents can 
inhibit TNF bioactivity in the circulation, they have no discern-
ible effect on in vivo TNF activity at the site of an acute immune 
challenge.
Our data fundamentally challenge the long held view that anti-
TNF agents mediate their therapeutic effect in RA by targeting 
TNF activity at the site of disease. We speculate that anti-TNF 
agents do not reach sufficient concentration within the tissue 
microenvironment to neutralize the level of TNF produced in an 
acute cell-mediated immune response. It remains possible that 
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they can inhibit lower levels of TNF at foci of chronic inflam-
mation. Alternatively, their therapeutic effects may be mediated 
by neutralizing the actions of circulating TNF, suggesting a 
previously unrecognized model by which TNF may contribute 
to the pathogenesis of RA. Further evaluation of this hypothesis 
may yield new mechanistic insights into the systemic immuno-
pathology of RA and other inflammatory diseases amenable to 
anti-TNF therapies.
eThics sTaTeMenT
This study was approved by UK National Research Ethics Service 
(reference no: 11/LO/1863), and written informed consent was 
obtained from all participants.
aUThOr cOnTriBUTiOns
RB-M, MRE, and MN designed the experiments. RB-M, CT, 
NG, and LB conducted the experiments. RB-M, CT, GP, ME, and 
MN undertook the analysis. RB-M, CT, MRE, and MN wrote the 
paper with input from all other authors.
acKnOWleDgMenTs
The authors thank Joanne Williams and Victoria Howard (UCL) 
and the Clinical Research Facility at University College London 
Hospital for their help in patient recruitment and sampling. The 
authors also thank Dr. Henry Penn and Dr. Shahir Hamdulay for 
their help in patient recruitment from Northwick Park Hospital.
FUnDing
This work was supported by an Arthritis Research UK Clinical 
Research Fellowship awarded to RB-M (20131), a Wellcome Trust 
Fellowship to GP (WT101766/Z/13/Z), the Medical Research Council 
(MR/M003833/1), and the National Institute for Health Research 
University College London Hospitals Biomedical Research Centre.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2017.00932/
full#supplementary-material.
reFerences
1. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflam-
matory responses in TNF alpha-deficient mice: a critical requirement for 
TNF alpha in the formation of primary B cell follicles, follicular dendritic cell 
networks and germinal centers, and in the maturation of the humoral immune 
response. J Exp Med (1996) 184(4):1397–411. doi:10.1084/jem.184.4.1397 
2. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, et  al. 
Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci 
U S A (1997) 94(15):8093–8. doi:10.1073/pnas.94.15.8093 
3. Wellmer A, Gerber J, Ragheb J, Zysk G, Kunst T, Smirnov A, et al. Effect of defi-
ciency of tumor necrosis factor alpha or both of its receptors on Streptococcus 
pneumoniae central nervous system infection and peritonitis. Infect Immun 
(2001) 69(11):6881–6. doi:10.1128/IAI.69.11.6881-6886.2001 
4. Botha T, Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient 
mice. J Immunol (2003) 171(6):3110–8. doi:10.4049/jimmunol.171.6.3110 
5. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor 
antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 
(2008) 117(2):244–79. doi:10.1016/j.pharmthera.2007.10.001 
6. Brzustewicz E, Bryl E. The role of cytokines in the pathogenesis of rheumatoid 
arthritis – practical and potential application of cytokines as biomarkers and 
targets of personalized therapy. Cytokine (2015) 76(2):527–36. doi:10.1016/j.
cyto.2015.08.260 
7. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune 
diseases. Nat Rev Drug Discov (2010) 9(6):482–93. doi:10.1038/nrd3030 
8. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged 
sword. Nat Rev Immunol (2003) 3(9):745–56. doi:10.1038/nri1184 
9. Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev 
Immunol (2005) 23:787–819. doi:10.1146/annurev.immunol.23.021704.115719 
10. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell (1996) 
85(3):307–10. doi:10.1016/S0092-8674(00)81109-5 
11. Choy E. Understanding the dynamics: pathways involved in the pathogenesis 
of rheumatoid arthritis. Rheumatology (Oxford) (2012) 51(Suppl 5):v3–11. 
doi:10.1093/rheumatology/kes113 
12. Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target 
of rheumatologic disease. Expert Opin Ther Targets (2007) 11(11):1369–84. 
doi:10.1517/14728222.11.11.1369 
13. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Ishida H, et al. Long-term 
follow-up of the changes in circulating cytokines, soluble cytokine receptors, 
and white blood cell subset counts in patients with rheumatoid arthritis (RA) 
after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol (1999) 
19(5):305–13. doi:10.1023/A:1020543625282 
14. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC. 
Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis 
down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 
(2000) 43(11):2391–6. doi:10.1002/1529-0131(200011)43:11<2391:AID- 
ANR3>3.0.CO;2-F 
15. Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, 
van den Berg WB. Effects of treatment with a fully human anti-tumour necro-
sis factor alpha monoclonal antibody on the local and systemic homeostasis of 
interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum 
Dis (2001) 60(7):660–9. doi:10.1136/ard.60.7.660 
16. Edrees AF, Misra SN, Abdou NI. Anti-tumor necrosis factor (TNF) therapy 
in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical 
response and benefit from changing dose or frequency of infliximab infusions. 
Clin Exp Rheumatol (2005) 23(4):469–74. 
17. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation 
of cytokines, cytokine inhibitors, and acute-phase proteins following anti-
TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 163(3):1521–8. 
18. Schuerwegh AJ, Van Offel JF, Stevens WJ, Bridts CH, De Clerck LS. Influence 
of therapy with chimeric monoclonal tumour necrosis factor-alpha antibod-
ies on intracellular cytokine profiles of T  lymphocytes and monocytes in 
rheumatoid arthritis patients. Rheumatology (Oxford) (2003) 42(4):541–8. 
doi:10.1093/rheumatology/keg171 
19. Schotte H, Schluter B, Willeke P, Mickholz E, Schorat MA, Domschke W, 
et al. Long-term treatment with etanercept significantly reduces the number 
of proinflammatory cytokine-secreting peripheral blood mononuclear 
cells in patients with rheumatoid arthritis. Rheumatology (Oxford) (2004) 
43(8):960–4. doi:10.1093/rheumatology/keh178 
20. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNFa therapy induces a distinct 
regulatory T cell population in patients with rheumatoid arthritis via TGF-B. 
J Exp Med (2007) 204(1):33–9. doi:10.1084/jem.20061531 
21. Nguyen DX, Ehrenstein MR. Anti-TNF drives regulatory T  cell expansion 
by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid 
arthritis. J Exp Med (2016) 213(7):1241–53. doi:10.1084/jem.20151255 
22. Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of 
action of anti-TNF-alpha agents – comparison among therapeutic TNF-alpha 
antagonists. Cytokine (2016). doi:10.1016/j.cyto.2016.08.014 
23. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, 
et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha 
12
Byng-Maddick et al. TNF Activity following Anti-TNF Treatment
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 932
neutralising agent. N Engl J Med (2001) 345(15):1098–104. doi:10.1056/
NEJMoa011110 
24. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous 
infectious diseases associated with tumor necrosis factor antagonists. Clin 
Infect Dis (2004) 38(9):1261–5. doi:10.1086/383317 
25. van Crevel R, Ottenhoff TH, van der Meer JW. Innate immunity to Mycobacterium 
tuberculosis. Clin Microbiol Rev (2002) 15(2):294–309. doi:10.1128/ 
CMR.15.2.294-309.2002 
26. Bean AGD, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, et al. 
Structural deficiencies in granuloma formation in TNF gene-targeted mice 
underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis 
infection, which is not compensated for by lymphotoxin. J Immunol (1999) 
162:3504–11. 
27. Roach DR, Bean AGD, Demangel C, France MP, Briscoe H, Britton WJ. TNF 
regulates chemokine induction essential for cell recruitment, granuloma 
formation, and clearance of mycobacterial infection. J Immunol (2002) 
168(9):4620–7. doi:10.4049/jimmunol.168.9.4620 
28. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. 
Tumor necrosis factor-alpha is required in the protective immune response 
against Mycobacterium tuberculosis in mice. Immunity (1995) 2(6):561–72. 
doi:10.1016/1074-7613(95)90001-2 
29. Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D, Chan J, et  al. 
Neutralization of tumor necrosis factor (TNF) by antibody but not TNF 
receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect 
Dis (2007) 195(11):1643–50. doi:10.1086/517519 
30. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al. Risk 
of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody 
therapy than with soluble tumor necrosis factor receptor therapy: the three-
year prospective French Research Axed on Tolerance of Biotherapies registry. 
Arthritis Rheum (2009) 60(7):1884–94. doi:10.1002/art.24632 
31. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. 
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated 
with anti-TNF therapy: results from the British Society for Rheumatology 
Biologics Register (BSRBR). Ann Rheum Dis (2010) 69:522–8. doi:10.1136/
ard.2009.118935 
32. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, 
et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients 
receiving anti-TNF therapy reported to the 3-year prospective French RATIO 
registry. Ann Rheum Dis (2011) 70(4):616–23. doi:10.1136/ard.2010.137422 
33. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. 
Infliximab induces apoptosis in monocytes from patients with chronic active 
Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 
(2001) 121(5):1145–57. doi:10.1053/gast.2001.28702 
34. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab 
treatment induces apoptosis of lamina propria T  lymphocytes in Crohn’s 
disease. Gut (2002) 50(2):206–11. doi:10.1136/gut.50.2.206 
35. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, et al. 
Evidence that anti-tumor necrosis factor therapy with both etanercept and 
infliximab induces apoptosis in macrophages, but not lymphocytes, in rheu-
matoid arthritis joints: extended report. Arthritis Rheum (2005) 52(1):61–72. 
doi:10.1002/art.20764 
36. Bruns H, Meinken C, Schauenberg P, Harter G, Kern P, Modlin RL, et  al. 
Anti-TNF immunotherapy reduces CD8+ T  cell-mediated antimicrobial 
activity against Mycobacterium tuberculosis in humans. J Clin Invest (2009) 
119:1167–77. doi:10.1172/JCI38482 
37. Tomlinson GS, Cashmore TJ, Elkington PTG, Yates J, Lehloenya RJ, Tsang J, 
et  al. Transcriptional profiling of innate and adaptive human immune 
responses to mycobacteria in the tuberculin skin test. Eur J Immunol (2011) 
41:3253–60. doi:10.1002/eji.201141841 
38. Bell LC, Pollara G, Pascoe M, Tomlinson GS, Lehloenya RJ, Roe J, et  al.  
In vivo molecular dissection of the effects of HIV-1 in active tuberculosis. PLoS 
Pathog (2016) 12(3):e1005469. doi:10.1371/journal.ppat.1005469 
39. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. 
Global burden of tuberculosis: estimated incidence, prevalence, and mortality 
by country. WHO Global Surveillance and Monitoring Project. JAMA (1999) 
282(7):677–86. doi:10.1001/jama.282.7.677 
40. Pollara G, Murray MJ, Heather JM, Byng-Maddick R, Guppy N, Ellis M, et al. 
Validation of immune cell modules in multicellular transcriptomic data. PLoS 
One (2017) 12(1):e0169271. doi:10.1371/journal.pone.0169271 
41. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, 
van Riel PL. Modified disease activity scores that include twenty-eight-joint 
counts. Development and validation in a prospective longitudinal study 
of patients with rheumatoid arthritis. Arthritis Rheum (1995) 38(1):44–8. 
doi:10.1002/art.1780380107 
42. van Riel PL, Renskers L. The disease activity score (DAS) and the disease activ-
ity score using 28 joint counts (DAS28) in the management of rheumatoid 
arthritis. Clin Exp Rheumatol (2016) 34(5 Suppl 101):S40–4. 
43. Tomlinson GS, Bell LC, Walker NF, Tsang J, Brown JS, Breen R, et  al. 
HIV-1 infection of macrophages dysregulates innate immune responses to 
Mycobacterium tuberculosis by inhibition of interleukin-10. J Infect Dis (2014) 
209(7):1055–65. doi:10.1093/infdis/jit621 
44. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, 
Cardinale I, et  al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate 
distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 
(2008) 159(5):1092–102. doi:10.1111/j.1365-2133.2008.08769.x 
45. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, 
et  al. Molecular signatures of antibody responses derived from a systems 
biology study of five human vaccines. Nat Immunol (2014) 15(2):195–204. 
doi:10.1038/ni.2789 
46. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and 
emerging therapeutic strategies. Nat Rev Rheumatol (2016) 12(1):49–62. 
doi:10.1038/nrrheum.2015.169 
47. Noursadeghi M, Tsang J, Miller RF, Straschewski S, Kellam P, Chain BM, et al. 
Genome-wide innate immune responses in HIV-1-infected macrophages are 
preserved despite attenuation of the NF-kappa B activation pathway. J Immunol 
(2009) 182(1):319–28. doi:10.4049/jimmunol.182.1.319 
48. Tsang J, Chain BM, Miller RF, Webb BL, Barclay W, Towers GJ, et al. HIV-1 
infection of macrophages is dependent on evasion of innate immune 
cellular activation. AIDS (2009) 23(17):2255–63. doi:10.1097/QAD. 
0b013e328331a4ce 
49. Ishihara K, Hirano T. Molecular basis of the cell specificity of cytokine 
action. Biochim Biophys Acta (2002) 1592(3):281–96. doi:10.1016/
S0167-4889(02)00321-X 
50. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test 
predicts the disease course during 3 years in early rheumatoid arthritis (the 
Swedish TIRA project). Ann Rheum Dis (2004) 63(9):1085–9. doi:10.1136/
ard.2003.016808 
51. Tsai CL, Chen WC, Hsieh HL, Chi PL, Hsiao LD, Yang CM. TNF-alpha 
induces matrix metalloproteinase-9-dependent soluble intercellular 
adhesion molecule-1 release via TRAF2-mediated MAPKs and NF-kappaB 
activation in osteoblast-like MC3T3-E1 cells. J Biomed Sci (2014) 21:12. 
doi:10.1186/1423-0127-21-12 
52. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. 
Transgenic mice expressing human tumour necrosis factor: a predictive 
genetic model of arthritis. EMBO J (1991) 10(13):4025–31. 
53. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, 
et  al. Anti-TNF therapy is associated with an increased risk of serious 
infections in patients with rheumatoid arthritis especially in the first 
6  months of treatment: updated results from the British Society for 
Rheumatology Biologics Register with special emphasis on risks in the elderly. 
Rheumatology (Oxford) (2011) 50(1):124–31. doi:10.1093/rheumatology/ 
keq242 
54. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept 
for active Crohn’s disease: a randomized, double-blind, placebo-controlled 
trial. Gastroenterology (2001) 121(5):1088–94. doi:10.1053/gast.2001. 
28674 
55. Varley KE, Gertz J, Bowling KM, Parker SL, Reddy TE, Pauli-Behn F, et al. 
Dynamic DNA methylation across diverse human cell lines and tissues. 
Genome Res (2013) 23(3):555–67. doi:10.1101/gr.147942.112 
56. Aota K, Azuma M. Targeting TNF-alpha suppresses the production of 
MMP-9 in human salivary gland cells. Arch Oral Biol (2013) 58(12):1761–8. 
doi:10.1016/j.archoralbio.2013.09.004 
57. Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor- 
alpha bioactivity in rheumatoid arthritis patients treated with infliximab: 
link to clinical response. Arthritis Res Ther (2005) 7(1):R149–55. doi:10.1186/
ar1465 
58. Denarie D, Rinaudo-Gaujous M, Thomas T, Paul S, Marotte H. Methotrexate 
reduced TNF bioactivity in rheumatoid arthritis patients treated with 
13
Byng-Maddick et al. TNF Activity following Anti-TNF Treatment
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 932
infliximab. Mediators Inflamm (2017) 2017:3708250. doi:10.1155/2017/ 
3708250 
Conflict of Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2017 Byng-Maddick, Turner, Pollara, Ellis, Guppy, Bell, Ehrenstein and 
Noursadeghi. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in other 
forums is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic practice. 
No use, distribution or reproduction is permitted which does not comply with these terms.
